Chugai Pharmaceutical Stock (OTC:CHGCF), Trade Ideas

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19 patients.

CHUGAI PHARMACEUTICAL by Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co Ltd

Chugai Pharmaceutical GAAP EPS of ¥142.37, revenue of ¥837.55B

Week In Review: SystImmune Out-Licenses Global Rights For ADC To BMS In $8.4B Deal

Quality stocks that would outperform in 2024 - UBS

Chugai Pharmaceutical Co., Ltd. 2023 Q4 - Results - Earnings Call Presentation

Chugai Pharmaceutical reports FY results

Week In Review: LianBio To Close Operations; Will Pay $528M To Shareholders

Argenx gains after setback to Roche/Chugai myasthenia gravis therapy

Chugai Pharmaceutical reports Q1 results

Chugai Pharmaceutical Co., Ltd. 2024 Q1 - Results - Earnings Call Presentation

Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2024 Earnings Call Transcript

ACGL

ACWI

AMZN

ANPDY

ARGX

AZNCF

BMYMP

BYDDF

CASI

CHGCF

CHGCY

CNTB

CONIF

CSPHF

FCNCA

HALO

LIAN

MGDDF

NFPDF

PCCYF

REGN

RHHBF

RHHBY

SFOSF

SHZHY

TTNDY

Chugai Pharmaceutical